PCSK9-IN-29
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity[1].
Product Specifications
CAS Number
1233353-86-0
UNSPSC
12352101
Target
LDLR; PCSK9
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/pcsk9-in-29.html
Purity
99.44
Solubility
DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(OC1=C(CN2CCC3=CC(OC)=C(C=C3C2C4)OC)C4=CC=C1OC)(C5=CC(F)=CC=C5)=O
Molecular Formula
C26H26FNO6S
Molecular Weight
499.55
References & Citations
[1]Liu, jing wen, et al. NASH、NAFLD 、. China, CN115279755A. 2022-11-01.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Rat IgG (H&L) Antibody Alkaline Phosphatase Conjugated Pre-Adsorbed
Myeloid-Associated Differentiation Marker (MYADM/971), CF647 conjugate, 0.1mg/mL
IL3RA / CD123 (Acute Myeloid Leukemia Marker) (IL3RA/2947R), CF405S conjugate, 0.1mg/mL
